Desmopressin (DDAVP)
Also known as: DDAVP, Minirin, 1-deamino-8-D-arginine vasopressin, dDAVP
Overview
Desmopressin (DDAVP) is a synthetic analog of arginine vasopressin (antidiuretic hormone, ADH) with two structural modifications: deamination of the N-terminal cysteine and substitution of L-arginine with D-arginine at position 8. These modifications eliminate the vasopressor activity present in native vasopressin and extend the antidiuretic half-life from minutes to 6–8 hours. FDA-approved for central diabetes insipidus, primary nocturnal enuresis, nocturia, and hemophilia A/von Willebrand disease (via V2/V1b receptor-mediated factor VIII and vWF release), desmopressin is one of the most widely used peptide drugs in endocrinology.
Mechanism of Action
Desmopressin selectively activates V2 receptors (kidney collecting duct, hepatocytes, endothelium) via Gs/cAMP/PKA signaling, causing aquaporin-2 (AQP2) insertion into collecting duct apical membranes and maximal water reabsorption (antidiuresis). V1b/V3 receptor activation in pituitary corticotrophs releases ACTH (relevant for testing). Endothelial V2 activation releases von Willebrand factor (vWF) and factor VIII from Weibel-Palade bodies, explaining its use in hemophilia A and vWD type 1. Unlike vasopressin, desmopressin has negligible V1a (vasopressor) activity.
Potential Benefits
- Central diabetes insipidus management
- Nocturnal enuresis and nocturia treatment
- Hemophilia A and vWD type 1 bleeding treatment/prophylaxis
- DDAVP stimulation test for cortisol/ACTH reserve assessment
- Long duration of action (6-8 hours) vs. native vasopressin (minutes)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 10 mcg intranasal or 0.1 mg oral at bedtime (enuresis) |
| Intermediate | 10-20 mcg intranasal 2x daily (central DI) |
| Advanced | 20 mcg intranasal 3x daily or 0.4 mg oral 3x daily (severe DI) |
| Cycle Duration | Chronic for central DI; short-term for enuresis |
FDA-approved (DDAVP, Stimate, Nocdurna) for central DI, nocturnal enuresis, nocturia, mild hemophilia A, and von Willebrand disease (Stimate high-dose). Monitor serum sodium — hyponatremia risk.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intranasal ~3-5%
Standard metered spray or rhinyle catheter. Stimate is concentrated formulation for hemostasis.
Oral (tablet, Nocdurna sublingual) ~0.1% oral, ~0.25% sublingual
Take on empty stomach. Nocdurna sublingual melts for nocturia.
Intravenous/Subcutaneous ~100% IV
Hospital use for hemostasis or acute DI.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Desmopressin (DDAVP):
Hemostasis Protocol
Pre-procedure hemostasis for mild hemophilia A or vWD — Stimate intranasal + tranexamic acid.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Nasal spray/tablets: room temperature. Ampoules/Stimate: refrigerate 2-8°C. |
|---|
Nasal Stimate requires refrigeration until first use.
Need exact syringe measurements?
Amino Acid Sequence
1-deamino-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2
Side Effects & Safety
- Hyponatremia (dilutional; serious if fluid intake not restricted)
- Headache and nausea
- Nasal irritation (intranasal formulation)
- Rare: thrombotic events (via vWF release at high doses)
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- SSRIs, NSAIDs, Carbamazepine, Loop Diuretics:
FDA Safety Information
FDA Boxed Warning (intranasal formulations for nocturia): Risk of severe hyponatremia leading to seizures, coma, and death.
Pharmacokinetics
| Half-Life | ~75 minutes (IV); oral effect 6-12 h; nasal 8-12 h |
|---|---|
| Storage | Nasal spray/tablets: store at room temperature. Stimate and injectable forms: refrigerate 2-8°C. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside Desmopressin (DDAVP) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.